Methotrexate & DMARD safety
A UK pharmacy guide to safe weekly methotrexate use, folic acid, risk-based monitoring, toxicity, interactions, pregnancy and OSCE counselling.
This guide covers low-dose methotrexate used for non-cancer conditions, particularly inflammatory rheumatological and dermatological disease. Oncology and ectopic-pregnancy regimens are different and must not be inferred from this article.
Methotrexate is effective, familiar and often first line, but preventable harm still occurs through daily dosing, missed monitoring, renal deterioration and interacting medicines. The safest consultation combines one unmistakable dosing message with a systematic toxicity check.
The six rules to remember
- Methotrexate is taken once weekly, not daily, for these non-cancer indications.
- Agree and document the same day each week.
- Co-prescribe folic acid; the 2025 British Society for Rheumatology guideline recommends at least 5 mg once weekly, not on the methotrexate day.
- Check full blood count, liver function and renal function according to the patient’s risk-stratified monitoring plan.
- Avoid trimethoprim and co-trimoxazole because severe, delayed bone-marrow suppression can occur.
- New mouth ulcers, sore throat, fever, unexplained bruising or bleeding, or new breathlessness need prompt assessment.
In an OSCE, say “once weekly” early, then ask the patient to tell you which day they take it. That teach-back is safer than simply asking, “Do you understand?”
Why once-weekly errors are so dangerous
For inflammatory disease, methotrexate is normally prescribed as a weekly dose. If a weekly dose is accidentally taken every day, the cumulative exposure can cause severe mucositis, gastrointestinal injury, pancytopenia, infection, bleeding, renal failure and death.
A safe medicines-reconciliation check should record:
- the exact weekly dose in milligrams
- the formulation and tablet strength
- the agreed day of the week
- the last dose taken and the next dose due
- the folic-acid regimen
- the indication and specialist team
- the monitoring plan and latest results
Do not record only “methotrexate, as directed”. If there is any uncertainty about the dose or day, withhold administration until the prescription and patient-held information have been reconciled.
Local systems commonly standardise oral treatment to 2.5 mg tablets to reduce strength-selection errors. Follow the local shared-care and dispensing policy, and avoid changing tablet strength without explicit counselling.
How methotrexate works
Methotrexate is a folate antagonist. At low weekly doses its anti-inflammatory effects are more complex than simple cytotoxicity, but the same folate-related biology helps explain mucosal and marrow toxicity.
Folic acid reduces common adverse effects and treatment discontinuation. It is not a substitute for monitoring and should not be taken on the methotrexate day under the current BSR regimen.
Before treatment starts
The initiating specialist assesses benefit, comorbidity, infection risk and the patient’s ability to follow weekly dosing and monitoring. A practical baseline review includes:
| Area | What to check | Why it matters |
|---|---|---|
| Blood count | FBC and relevant clinical history | Detect pre-existing cytopenia |
| Liver | LFTs, alcohol intake, metabolic and liver-disease risk | Methotrexate can contribute to hepatotoxicity |
| Kidney | Serum creatinine and eGFR or creatinine-clearance context | Methotrexate is mainly cleared renally; accumulation increases toxicity |
| Infection | Clinical infection, hepatitis risk and other tests indicated by the specialty | Immunosuppression can worsen infection or reactivate disease |
| Vaccination | Vaccination history and planned live vaccines | Timing may need specialist planning |
| Pregnancy | Pregnancy status and reproductive plans where relevant | Methotrexate must be avoided in pregnancy |
| Medicines | Prescription, OTC, herbal and recent antibiotics | Interactions are a major preventable cause of harm |
| Understanding | Weekly schedule, monitoring and toxicity symptoms | The 2025 BSR guideline requires ability to understand and comply with weekly dosing |
The 2025 BSR guidance does not recommend routine lung screening for everyone before a conventional DMARD. Lung assessment should be driven by the diagnosis, symptoms and examination findings. This is a useful example of why old monitoring mnemonics should not replace current guidance.
Monitoring: think risk, trend and action
The 2025 BSR guideline uses risk-stratified monitoring rather than one schedule for every patient. Risk assessment considers comorbidities, medicines, alcohol, BMI, kidney function, liver function and baseline blood results.
| Risk pattern | Example | First-year principle |
|---|---|---|
| Lower risk | Normal baseline tests, no significant comorbidity | Early test after initiation, monthly tests initially, then progressively longer intervals if stable |
| Medium risk | Metabolic or liver-risk factors, several comorbidities | Monthly monitoring continues longer before the interval is extended |
| Higher risk | Borderline renal function, multiple comorbidities or interacting medicines | More frequent early monitoring and continued closer review |
The exact schedule belongs in the specialist or shared-care plan. The core tests are generally:
- FBC for leucopenia, neutropenia, thrombocytopenia and macrocytosis
- LFTs and albumin for hepatotoxicity and trend
- serum creatinine and renal function for impaired elimination
Do not look only for a result crossing a threshold. A falling white-cell or platelet count, rising transaminases or worsening renal function can represent toxicity even if each individual result is still within the laboratory reference range.
If a result changes significantly, check the current shared-care threshold, withhold if directed and contact the treating team. Do not silently issue a repeat prescription when required monitoring is missing or unreviewed.
Recognising toxicity
Bone-marrow suppression
Ask about:
- sore throat, fever, chills or recurrent infection
- mouth ulcers or severe mucositis
- unexplained bruising, petechiae or bleeding
- new shortness of breath, fatigue or pallor
These symptoms warrant prompt clinical review and an FBC. Severe toxicity may present after an interacting medicine has finished, particularly with trimethoprim or co-trimoxazole.
Liver injury
Ask about nausea, abdominal symptoms, dark urine, jaundice, pruritus and alcohol intake, while remembering that abnormal LFTs may be asymptomatic. Assess other hepatotoxic medicines and the trend in results.
Pulmonary toxicity
A new persistent dry cough, breathlessness, hypoxia or fever may indicate methotrexate pneumonitis, but infection and disease-related lung pathology are important alternatives. Withhold and obtain urgent specialist assessment rather than reassuring the patient on the basis of a previously normal chest X-ray.
Renal deterioration
Dehydration, acute kidney injury or a nephrotoxic medicine can reduce methotrexate clearance. A previously tolerated weekly dose can therefore become unsafe when the clinical context changes.
High-yield interactions
| Medicine or group | Mechanism or concern | Practical response |
|---|---|---|
| Trimethoprim or co-trimoxazole | Additive antifolate effect and altered methotrexate handling can cause severe marrow suppression | Avoid; discuss alternatives with microbiology or the specialist |
| NSAIDs | Reduced renal elimination and renal toxicity, particularly at higher methotrexate exposure or in renal impairment | Use only with specialist awareness; advise against unsupervised OTC NSAIDs |
| Penicillins | May reduce renal clearance | Short courses may sometimes be used with caution; counsel on toxicity and follow current interaction guidance |
| Proton-pump inhibitors | Possible reduced clearance; clinical significance is greater at high dose or with renal impairment | Usually monitor through the established plan, but review individual risk |
| Other hepatotoxic medicines or excess alcohol | Additive liver risk | Review necessity, monitoring and alcohol advice |
| Other marrow-suppressing medicines | Additive cytopenia risk | Seek specialist advice and consider enhanced monitoring |
Interaction management depends on indication, dose, duration, renal function and the patient’s monitoring plan. The answer is not always “stop everything”, but it is never “ignore the interaction”.
Infection, vaccination and procedures
The 2025 BSR guideline recommends temporarily discontinuing conventional DMARDs during a severe infection, such as one requiring intravenous treatment or hospital admission, until the person has recovered. Management of mild infections is more individualised; follow the specialist or shared-care plan rather than inventing a blanket rule.
Vaccination should be reviewed before and during immunosuppression. Inactivated vaccines are generally usable, while live-vaccine decisions depend on the degree of immunosuppression and current national guidance.
Conventional DMARDs should not routinely be stopped for every operation. Perioperative decisions are individualised for the procedure, disease control and infection risk.
Pregnancy, breastfeeding and paternal exposure
Methotrexate should be avoided in pregnancy. The BSR pregnancy guideline recommends stopping maternal methotrexate at least one month before planned conception and switching to a pregnancy-compatible medicine so that the underlying disease remains controlled.
If pregnancy occurs during low-dose treatment:
- stop methotrexate
- seek urgent specialist advice
- arrange early fetal-medicine risk assessment as advised
- use the folic-acid plan recommended by the specialist
Methotrexate is not recommended during breastfeeding in the current BSR guidance because outcome data are insufficient.
An important correction to older teaching is that low-dose paternal methotrexate exposure is considered compatible with pregnancy by current BSR evidence. Do not automatically tell a male patient to stop treatment for three months; check current specialist guidance and the individual situation.
Other conventional DMARDs: do not apply methotrexate rules blindly
| DMARD | Distinctive safety point |
|---|---|
| Sulfasalazine | FBC and liver monitoring; may cause reversible reduction in sperm count; folate advice matters in pregnancy |
| Hydroxychloroquine | Retinal-toxicity risk requires dose awareness and ophthalmic-monitoring pathways |
| Leflunomide | Long half-life, liver and blood-count monitoring; cholestyramine washout may be needed in specific situations |
| Azathioprine | TPMT status is assessed before treatment; NUDT15 or other factors may be relevant in some patients |
| Ciclosporin | Blood pressure, renal function and multiple pharmacokinetic interactions are central |
| Biologic or targeted DMARDs | Infection screening and vaccination planning are medicine specific; they are not interchangeable with conventional DMARD monitoring |
A pharmacy OSCE counselling structure
- Confirm the medicine: indication, weekly dose, tablet strength and day.
- Use teach-back: “Which day will you take methotrexate, and when will you take folic acid?”
- Explain benefit and onset: improvement is gradual; continue as directed unless advised otherwise.
- Explain monitoring: what blood tests are needed, who reviews them and what happens if they are missed.
- Cover toxicity: mouth ulcers, sore throat, fever, bruising, bleeding, jaundice, new cough or breathlessness.
- Check interactions: antibiotics, OTC ibuprofen or aspirin, herbal products and alcohol.
- Discuss infection and vaccines: contact the clinical team for a severe infection and before live vaccination.
- Discuss reproductive plans sensitively: give current, sex-specific advice and involve the specialist.
- Safety-net: do not take an extra dose after a missed dose without checking the patient information or contacting the team.
Common mistakes
- Saying “daily” at any point in relation to low-dose inflammatory-disease treatment.
- Failing to verify the dose in milligrams and the day of the week.
- Assuming folic acid can be taken on the same day.
- Quoting one monitoring schedule without checking risk or specialty.
- Prescribing trimethoprim for a UTI without noticing methotrexate.
- Treating a new cough as a minor expected adverse effect.
- Advising all men to stop low-dose methotrexate before conception.
- Continuing repeats when blood tests are overdue or results have not been reviewed.
Check your understanding
Why can an interaction appear after years of stable treatment? A new antibiotic, NSAID, dehydration or renal deterioration can reduce elimination or add marrow toxicity, changing the safety of the same weekly dose.
What is the highest-value counselling question? Ask the patient to state the methotrexate day and folic-acid day in their own words.
Why are trends important? Toxicity can develop progressively before a value crosses a fixed stopping threshold.
Authoritative sources and further reading
- British Society for Rheumatology: 2025 csDMARD prescribing and monitoring guideline
- NHS Specialist Pharmacy Service: methotrexate monitoring
- NHS Specialist Pharmacy Service: managing interactions with methotrexate
- British Society for Rheumatology: prescribing in pregnancy and breastfeeding
- NHS England national shared-care protocol for methotrexate
Last clinically reviewed: 15 August 2026. Educational reference for UK healthcare students; always use the current BNF, specialist plan, shared-care protocol and local policy for patient care.